2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. - Wikidata - wikimedia - TriplyDB

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

http://www.wikidata.org/entity/Q34779270

about

Current perspectives on HIV-1 antiretroviral drug resistance 8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcription HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.Novel compounds for the treatment of HIV type-1 infection.Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.A proposed structure of modified nucleosides expected to have high antiviral activity and low toxicity.

P2860

Q26852626-C2F837AC-C7AA-4333-939F-3BA859402CEA Q28477840-A8981A68-88A8-4B68-8880-6DEEC5C2D5F0 Q28551618-D0732DA3-C52F-404D-8BE4-551286021CA7 Q28552730-4F10BECE-2C87-4029-8F38-EB49FC2E0A72 Q33819045-E78C6794-5329-4FE4-8A5F-3CF53CBAA894 Q33896402-48B92220-35B8-4DCB-852B-3B4499546FD5 Q34058234-3DBAE17C-6753-4FDB-AECB-A84ADC6D823C Q34059879-1C07B02B-FD4F-4A6D-ACBD-2E3CB093BD72 Q34107343-3D6D0D8C-BE62-4302-A168-FF3353FDC37E Q34303603-91AE91AB-09AD-48A2-98E3-16FDB626A058 Q34475019-F8615591-EA15-4D1E-AC2D-596D49ED708E Q35633587-9AD8B58B-3A33-4F5C-BFD9-04A4C4253031 Q35806294-A42E6326-1E2D-47C9-8041-8E666AFC0383 Q35929032-6A950F2B-3AC2-40E0-9055-52107852B2C4 Q36108952-2474747D-5EBB-4304-A0B1-7FFE10C9F735 Q36172536-EADE03CF-15AD-4451-B04B-0700800F9CC0 Q36276790-254321E4-B644-4BAE-B403-5FF91CE7A0E0 Q36290647-BBDA871C-4E64-44B0-9B88-A95E311A65A3 Q36553113-E50D173C-F275-4A15-ACC3-5DCC6E6BD065 Q36964321-6A751AC5-2B34-45C0-B689-3E7B3E031E45 Q37124096-694B3306-794D-4619-9AEE-24F2761E3E18 Q37200146-AA22257E-2E29-40AC-91E1-9B3B01085F31 Q37288671-8009DEAA-F58E-4ACA-9BC0-73324456B7ED Q37333100-F499CB04-BB0A-4C28-A797-9A7532B3BFB4 Q37335626-AED466E0-E10B-4C1C-BB83-15C1D404CDA2 Q37409900-4EDD87DF-2F95-4E10-8CAB-D94674F58C68 Q37467660-F81B9AD2-CDA7-42D6-915B-813A7AEDDEF3 Q37502492-BC8C5E27-06DC-409F-8481-4C6C8EB4FF5D Q37687006-8D69C748-E120-42C6-B6D5-288908E8F9BE Q38755690-5B564A05-17C2-4F6A-83B9-56ABD28CE762 Q39520219-215122AE-9BBB-453E-AAA7-9554107F1ECE Q39912641-3A9EEB7B-D88B-42E3-8B61-CA4A30D6E88C Q40925666-80793A68-0605-478E-905B-943F67C6CEF8 Q41879018-3ED423EF-7E8A-4C64-9CA4-5DA96CBA3136 Q41927879-4163FD10-9394-4B6D-B53D-02CB4F852CC9 Q42104244-CB335042-4B19-46E2-B3A2-761AD49BD537 Q42159090-5DE71312-1DF4-48D1-89E9-81DA767FA93F Q42182643-26FE4C1D-2599-45A8-BD32-F95B7E7D8C2B Q42766013-24860B1A-C570-4E5F-A647-23C5B5A9020C Q43150204-95F3D4A7-3AD9-4966-BA49-6C3E1FB8E1C6

P2860

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

http://www.wikidata.org/entity/Q34779270

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@ast

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@en

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@nl

type

label

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@ast

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@en

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@nl

prefLabel

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@ast

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@en

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@nl

P1433

Q34779270-9D9E2859-B37A-4A53-A8DF-528CB6A1F615

P1476

Q34779270-E7400F67-25CB-4466-B4EF-331FAA7868A8

P2093

Q34779270-2D3C10ED-4F8E-4589-B854-58D04824B0B6

Q34779270-47418A6B-A197-4A1E-BD18-6552729D9127

Q34779270-50C60075-37AF-4DBC-8B0C-A3AE3CE24447

Q34779270-59614825-7639-4EA1-A4B7-A0310CD95501

Q34779270-65619FFE-8D66-4759-A27D-863D34951D54

Q34779270-6E4D5B7C-3FDF-4045-82D2-28DFCD155D23

Q34779270-87AE117E-5147-4F15-8916-FEE9116C8F38

Q34779270-96F0E871-2DD2-4D50-BDCC-79982AA6CF8C

Q34779270-CE2FCE65-259C-49D9-A440-C9AA714DD68C

Q34779270-F97725D0-1A1F-4729-9E93-D5A7D8EC9A2B

P304

Q34779270-2582C92F-84DB-4DEC-963C-2CAC97279167

P31

Q34779270-678B8493-EB9F-429A-84C0-D359D132E11D

P356

Q34779270-72667FF7-025D-41AC-AB3B-01DF08058DCF

P433

Q34779270-83CE80B8-9844-4ED7-8F1A-1A308CEF6DC3

P478

Q34779270-A3D9A214-77AF-4EE0-B090-023BDBD1FD34

P50

Q34779270-5BE70923-D134-4658-9371-CBDCA8B5D1A5

Q34779270-80F80CD5-E568-492D-BAA9-AC4CFD3C6F46

Q34779270-F913C4C8-B3E4-40D4-8D50-E2A20BEAFB97

P577

Q34779270-F29AF369-216E-47F6-BE19-1871BE525A06

P698

Q34779270-AFD3192C-34EE-4727-8AAF-0801E11F3DF7

P356

J.BIOCEL.2008.04.007

P1433

International Journal of Biochemistry & Cell Biology

P1476

2'-deoxy-4'-C-ethynyl-2-halo-a ...... iciency virus type 1 variants.

@en

P2093

Atsushi Kawamoto

http://www.w3.org/2001/XMLSchema#string

Eddy Arnold

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mitsuya

http://www.w3.org/2001/XMLSchema#string

Hirotomo Nakata

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Hayakawa

http://www.w3.org/2001/XMLSchema#string

Kenji Kitano

http://www.w3.org/2001/XMLSchema#string

Noriyuki Ashida

http://www.w3.org/2001/XMLSchema#string

Satoru Kohgo

http://www.w3.org/2001/XMLSchema#string

Yasuko Sakagami

http://www.w3.org/2001/XMLSchema#string

Yuko Iwai

http://www.w3.org/2001/XMLSchema#string

P304

2410-2420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOCEL.2008.04.007

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Stefan G. Sarafianos

P577

2008-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18487070

http://www.w3.org/2001/XMLSchema#string